Afrocab has developed a FAQ (below) that covers the topics of PrEP and explains how CAB-LA works, is taken, and its side effects.
Cabotegravir Long-Acting Injectable for Prevention
Frequently Asked Questions
The Years Ahead in Biomedical HIV Prevention Research
[[DRAFT; UNPUBLISHED]]
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Media Science Cafes
AVAC Capability Statement
Since 2012, AVAC has worked to strengthen the capacity of journalists to report on HIV prevention research and global health and science topics. Through its flagship Media Science Café Program, AVAC partners with health media associations in Kenya, Malawi, Tanzania, Uganda, Zambia and Zimbabwe to connect journalists with subject matter experts—researchers, policymakers and advocates—and help build the relationships needed to foster accurate and informed reporting of HIV, COVID and emerging health and science issues.
Organizational Capability Statement
AVAC excels as a trusted convener, linking diverse stakeholders in HIV prevention and advancing global health equity through its 25+ years of expertise in advocacy, research, and policy development. We play a crucial role in driving the development, access, and adoption of innovative HIV prevention solutions—particularly in high-need communities—and swiftly respond to evolving health challenges worldwide.
AVAC Fellows Program
Capability Statement
The AVAC Fellows program empowers advocates to create lasting impact within their communities and beyond. Alumni often pursue further training, lead advocacy movements, and play significant roles in shaping health policies and national strategies.
Advocacy to Accelerate Prevention R&D for Sexually Transmitted Infections
AVAC Case for Support
AVAC accelerates the development and delivery of STI prevention options by fostering collaborations with STI and HIV research advocates, developing new STI vaccines and diagnostics, and creating tools to monitor STI research and investment activities.
Our Work with Key Populations
Capability Statement
AVAC advocates for effective HIV prevention, supports Key Population-led research participation, fights against criminalization policies, accelerates access to innovative prevention tools, and champions broader health equity issues.
Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025
HIV Vaccine and Antibody Efficacy Trials to Date
This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.
Joint Statement on the April 18th Revised Pandemic Accord Draft
The Coalition of Advocates for Global Health and Pandemic Preparedness, a group of organizations advocating for a holistic and equitable approach in pandemic preparedness, offers several revisions to the April 18 revised Pandemic Accord draft.